Answers are grounded in this paper and cite their sources.
Background: The purpose of this retrospective study was to investigate the predictive ability of the Ki67 labeling index (LI) for relapse-free survival (RFS) of patients with stage I-II invasive breast cancer after breast-conserving therapy.Materials and methods: Between 2012 and 2016, 240 patients with stage I-II invasive breast cancer were treated at our hospital with breast-conserving therapy. Survival outcomes were analyzed using the Kaplan-Meier and cumulative incidence methods. Factors including T stage, N stage, estrogen receptor, HER2, and Ki67 LI were evaluated with regard to RFS using Cox proportional hazard regression.Results: The median duration of follow-up in the surviving patients was 36 months (range, 14–62 months). Rates of 3-year overall survival and RFS were 98.1% and 96.4%, respectively. Three-year cumulative rates of local recurrence, regional recurrence, and distant metastasis were 1.3%, 1.2%, and 2.1%, respectively. Multivariate analysis revealed that a Ki67 LI ≥33.3% was the only prognostic factor for RFS.Conclusion: A Ki67 LI ≥33.3% was a predictor of significantly worse RFS.
No takes yet. Share an insight, caveat, or question.
Abe et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: